Contact us to learn more about

our Premium Content: News alerts, weekly reports and conference planners

DRUG:

nesuparib (JPI-547)

Contact us to learn more about our Premium Content:

News alerts, weekly reports and conference planners

Company:

Jeil

Drug class:

PARP inhibitor, TNKS inhibitor

Related drugs:

BRCA1 mutation	Ovarian Cancer	BRCA1 mutation	Ovarian Cancer	JPI-547 Sensitive: C2 – Inclusion Criteria JPI-547 Sensitive : C2	JPI-547 Sensitive: C2 – Inclusion Criteria JPI-547 Sensitive : C2
BRCA2 mutation	Non Small Cell Lung Cancer	BRCA2 mutation	Non Small Cell Lung Cancer	JPI-547 Sensitive: C4 – Case Studies JPI-547 Sensitive : C4	JPI-547 Sensitive: C4 – Case Studies JPI-547 Sensitive : C4
ATM mutation	Breast Cancer	ATM mutation	Breast Cancer	JPI-547 Sensitive: C4 – Case Studies JPI-547 Sensitive : C4	JPI-547 Sensitive: C4 – Case Studies JPI-547 Sensitive : C4
BRCA2 mutation	Breast Cancer	BRCA2 mutation	Breast Cancer	JPI-547 Sensitive: C4 – Case Studies JPI-547 Sensitive : C4	JPI-547 Sensitive: C4 – Case Studies JPI-547 Sensitive : C4
BRCA1 mutation	Breast Cancer	BRCA1 mutation	Breast Cancer	JPI-547 Sensitive: C4 – Case Studies JPI-547 Sensitive : C4	JPI-547 Sensitive: C4 – Case Studies JPI-547 Sensitive : C4
HRD	Pancreatic Ductal Adenocarcinoma	HRD	Pancreatic Ductal Adenocarcinoma	JPI-547 Sensitive: D – Preclinical JPI-547 Sensitive : D	JPI-547 Sensitive: D – Preclinical JPI-547 Sensitive : D
RNF43 mutation	Pancreatic Ductal Adenocarcinoma	RNF43 mutation	Pancreatic Ductal Adenocarcinoma	JPI-547 Sensitive: D – Preclinical JPI-547 Sensitive : D	JPI-547 Sensitive: D – Preclinical JPI-547 Sensitive : D